The Readout Loud

STAT

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Subscribe Listen in podnod RSS feed Show website

416 episodes
Updated Thursday

Episodes416

Newest first

Jul 18, 2024 · 33 min
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.
Jul 11, 2024 · 34 min
313: Biotech layoffs, founder-focused VC, & a big pharma exit
STAT's West Coast biotech reporter Jonathan Wosen joins "The Readout LOUD" to discuss what’s driving workforce cuts. Plus, entrepreneurs Alexis Borisy and Zach Weinberg call in to discuss their biotech incubator Curie.Bio and how they hope to “free the founders.” We also discuss a big change in Pfizer’s leadership and the debate over a new side effect tied to the diabetes drug Ozempic.
Jun 27, 2024 · 28 min
312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
STAT health tech reporter Brittany Trang guest co-hosts "The Readout LOUD" this week, where we discuss AI for drug development, the latest in the H5N1 bird flu outbreak, a surprise entrant to the GLP-1 field, and more news in the life sciences. And STAT chief Washington correspondent Rachel Cohrs Zhang joins the podcast to talk about a new proposal for obesity drug coverage in Washington and what to expect from the first presidential debate.
Jun 20, 2024 · 34 min
311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review
STAT reporter Jason Mast joins us to discuss Anthony Fauci's memoir "On Call," which was published this week. Hosts Allison DeAngelis and Adam Feuerstein also dissect Alnylam's forthcoming clinical trial data and take stock of how the biotech markets are succeeding and potentially falling flat midway through the year. For more on Fauci's memoir "On Call," go here; for Adam's primer on Alnylam's ATTR-CM trial, go here; read about BridgeBio's plans here; and for more on biotech startup financing, go here.
Jun 13, 2024 · 38 min
310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)
STAT's Nicholas Florko joins to explain what it means to be a reporter writing about the commercial determinants of health. Hint: Florko's most recent stories focus on weed, vapes, and raw milk. And instead of being chained to a desk, he often drives around to convenience stores and buy bad stuff — all in the name of good journalism. But first, co-hosts Adam Feuerstein and Allison DeAngelis chat about Pfizer's Duchenne gene therapy setback, the likely approval of a new treatment for Alzheimer's disease, and Bob Langer's most recent startup.
Jun 6, 2024 · 29 min
309: Psychedelics at the FDA, ASCO recap, & MorphoSys update
The one we recorded twice
May 30, 2024 · 28 min
308: An ASCO preview & another Duchenne trial failure
And more pronunciation difficulties
May 23, 2024 · 31 min
307: More tumult at BIO & coercive care for sickle cell patients
This week on “The Readout LOUD,” STAT's Chief Washington Correspondent Rachel Cohrs Zhang joins us to discuss the layoffs at trade group BIO and how things may be changing at the trade group. We also invite STAT reporter Eric Boodman on to talk about his new investigative series of stories exploring how Black women with sickle cell disease were coerced into getting sterilized.
May 16, 2024 · 23 min
306: Live! From the STAT Breakthrough Summit West
On this week’s "Readout LOUD," we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on that note, we chat with our AI correspondent — and recent Pulitzer finalist — Casey Ross, who sat down on stage to discuss AI-centered drug discovery with both NVIDIA and Google-backed Isomorphic Labs. We also discuss this week’s biotech news, including yet more obesity drug data, this time from Roche, and the closing of Novartis’ acquisition of MorphoSys.
May 9, 2024 · 31 min
305: Everything you need to know about H5N1 bird flu
It's the Pulitzer episode!
May 2, 2024 · 33 min
304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama
Please welcome Elaine Chen to the STAT biotech team!
Apr 18, 2024 · 31 min
303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
Eli Lilly, Novo Nordisk, Teladoc, oh my!
Apr 11, 2024 · 24 min
302: Vertex's big deal, biotech's red numbers, & an industry history lesson
And an annoucement :(
Apr 4, 2024 · 31 min
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
And where in the world is Damian?
Mar 28, 2024 · 34 min
300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Happy 300th birthday to us!
Mar 21, 2024 · 33 min
299: Live! From the STAT Breakthrough Summit East
With some nice "background murmering"
Mar 14, 2024 · 35 min
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
And a pie contest!
Mar 7, 2024 · 27 min
297: VC turmoil, GLP-1 competition, & the war on recovery
Why are addiction treatments so hard to get?
Feb 29, 2024 · 24 min
296: Legal insider trading, booming biotech stocks, & the next GLP-1
The dog days are ... over?
Feb 22, 2024 · 34 min
295: Humira’s legacy, CEO symbolism, and genomic surgery
What do CEOs owe the world?